IPC
ALXN

Independent Portfolio Consultants’s Alexion Pharmaceuticals ALXN Stock Holding History

Independent Portfolio Consultants’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$111K Sell
912
-153
-14% -$17.8K 0.05% 401
2017
Q1 		$129K Buy
1,065
+340
+47% +$43.8K 0.04% 398
2016
Q4 		$89K Buy
+725
New +$88.7K 0.03% 465
2015
Q3 		– Sell
-70
Closed -$13K – 888
2015
Q2 		$13K Sell
70
-996
-93% -$172K ﹤0.01% 747
2015
Q1 		$185K Sell
1,066
-91
-8% -$16.5K 0.04% 379
2014
Q4 		$214K Sell
1,157
-1,350
-54% -$250K 0.04% 355
2014
Q3 		$416K Sell
2,507
-105
-4% -$17.2K 0.11% 282
2014
Q2 		$408K Buy
2,612
+155
+6% +$24.5K 0.11% 311
2014
Q1 		$373K Sell
2,457
-3,410
-58% -$542K 0.12% 322
2013
Q4 		$780K Buy
5,867
+115
+2% +$13.8K 0.27% 104
2013
Q3 		$668K Sell
5,752
-70
-1% -$7.68K 0.27% 119
2013
Q2 		$537K Buy
+5,822
New +$561K 0.24% 163

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Independent Portfolio Consultants's ALXN Position: Q2 2017 in Review

Independent Portfolio Consultants reduced its Alexion Pharmaceuticals (ALXN) stake by 14% in Q2 2017, selling an estimated $17.8K and leaving 912 shares worth $111K. The position accounts for 0.05% of the portfolio, ranked #401.

Independent Portfolio Consultants first reported a position in ALXN in Q2 2013 and has held it in 12 quarters since. The position peaked at $780K in Q4 2013. 559 funds tracked by Wall St. Rank hold ALXN as of Q2 2017.

  • Independent Portfolio Consultants held 912 shares of Alexion Pharmaceuticals worth $111K as of Q2 2017.
  • Independent Portfolio Consultants sold 153 Alexion Pharmaceuticals shares in Q2 2017, an estimated $17.8K.
  • Alexion Pharmaceuticals made up 0.05% of Independent Portfolio Consultants's portfolio in Q2 2017, its #401 holding.
  • Independent Portfolio Consultants first reported a position in Alexion Pharmaceuticals in Q2 2013 and has held it in 12 quarters since.
  • Independent Portfolio Consultants's Alexion Pharmaceuticals position peaked at $780K in Q4 2013.
  • 559 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2017.

Based on Independent Portfolio Consultants's 13F filing for Q2 2017, filed 6 Jul 2017.